SCHEMBL5653711

SCHEMBL5653711

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccc(N3CCOCC3)cc2)c1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 4/20 0.44
HPGD P15428 2/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 5/20 0.44
POLB P06746 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
DNMT1 P26358 1/20 0.44
APEX1 P27695 1/20 0.44
RECQL P46063 1/20 0.44
CACNA1B Q00975 1/20 0.44
APBA1 Q02410 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
GRM6 O15303 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CSNK1D P48730 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650136 0.88 MAPT (0.51) LMNAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5650538 0.87 PPARG (0.49) LMNAALDH1A1KDM4EMAPTMEN1
SCHEMBL5650867 0.87 MAPT (0.47) LMNAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5652764 0.86 MAPT (0.45) LMNAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5652595 0.86 MAPT (0.45) LMNAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5654426 0.85 ALDH1A1 (0.50) LMNAALDH1A1KDM4EHPGDMAPT
SCHEMBL5652339 0.85 MAPT (0.44) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL5647395 0.85 MAPT (0.50) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL5652293 0.85 MAPT (0.44) LMNAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5648376 0.84 MEN1 (0.47) LMNAALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 LMNA 1417/4885ALDH1A1 1498/4885KDM4E 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.